ORKA
Oruka Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$74.48
+3.55%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.60
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$0.55
- EPS estimate
- -$0.51
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +7.9%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $159
- PT range
- $120 – $200
- Analysts
- 4
4 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 10, 2026 | -$0.51 | -$0.55 | Miss -7.32% | — |
| May 13, 2026 | -$0.52 | -$0.48 | Beat 7.69% | — |
| Mar 12, 2026 | -$0.64 | -$0.45 | Beat 29.26% | — |
| Nov 12, 2025 | -$0.56 | -$0.55 | Beat 1.79% | — |
| Feb 27, 2025 | -$0.68 | -$0.96 | Miss -41.18% | — |
| Nov 13, 2024 | -$0.40 | -$1.46 | Miss -265.00% | — |
| Apr 25, 2024 | — | -$0.14 | — | — |
| Sep 29, 2022 | — | -$1.94 | — | — |
| Jun 29, 2019 | — | -$14 | — | — |
| Sep 29, 2018 | — | -$25 | — | — |
| Dec 30, 2017 | — | -$77 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026